Pharma & Healthcare Update
April 01, 2021
Commercialisation of healthcare in India: overview
India is home to some of the world’s largest pharmaceutical companies and makes a significant contribution to the global output of drugs each year. India’s reputation as the pharmacy of the world has only grown in recent years. In the medical device sector as well, India is on its way to making a mark globally. The growth of the Indian pharmaceutical and medical device industry can be attributed in part to the well-established regulatory framework governing drugs and medical devices manufactured and marketed in India. Medicinal products have been regulated in India since the 1940s and the government has been making efforts in recent years to ensure the manner of regulating drugs and medical devices is in line with global standards. This has encouraged many foreign players to consider marketing their products in India as well as sourcing their products from India to meet the demand in other jurisdictions.
In this guide, Dr. Milind Antani, Darren Punnen and Shreya Shenolikar provide a comprehensive overview of the regulatory framework applicable to drugs and medical devices. The guide covers the entire supply chain from approval of drugs and medical devices to their sale to the end consumer. They have also provided information on the manner in which pharmaceutical adjacent products such as alternative medicinal products and nutraceuticals are regulated.
The complete article can be accessed here.
Reproduced from Practical Law with the permission of the publishers. For further information, visit practicallaw.com
Disclaimer
The contents of this hotline should
not be construed as legal opinion. View detailed disclaimer.
This hotline does not constitute a
legal opinion and may contain information generated
using various artificial intelligence (AI) tools or
assistants, including but not limited to our in-house
tool,
NaiDA. We strive to ensure the highest quality and
accuracy of our content and services. Nishith Desai
Associates is committed to the responsible use of AI
tools, maintaining client confidentiality, and adhering
to strict data protection policies to safeguard your
information.
This hotline provides general information
existing at the time of preparation. The Hotline is
intended as a news update and Nishith Desai Associates
neither assumes nor accepts any responsibility for any
loss arising to any person acting or refraining from
acting as a result of any material contained in this
Hotline. It is recommended that professional advice
be taken based on the specific facts and circumstances.
This hotline does not substitute the need to refer to
the original pronouncements.
This is not a spam email. You have
received this email because you have either requested
for it or someone must have suggested your name. Since
India has no anti-spamming law, we refer to the US directive,
which states that a email cannot be considered spam
if it contains the sender's contact information, which
this email does. In case this email doesn't concern
you, please
unsubscribe from mailing list.
|